We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy: A Randomized Clinical Trial.
- Authors
van Veldhuisen, Charlotte L.; Latenstein, Anouk E. J.; Blauw, Helga; Vlaskamp, Lyan B.; Klaassen, Michel; Lips, Daan J.; Bonsing, Bert A.; van der Harst, Erwin; Stommel, Martijn W. J.; Bruno, Marco J.; van Santvoort, Hjalmar C.; van Eijck, Casper H. J.; van Dieren, Susan; Busch, Olivier R.; Besselink, Marc G.; DeVries, J. Hans; Dutch Pancreatic Cancer Group
- Abstract
<bold>Importance: </bold>Glucose control in patients after total pancreatectomy is problematic because of the complete absence of α- and β-cells, leading to impaired quality of life. A novel, bihormonal artificial pancreas (BIHAP), using both insulin and glucagon, may improve glucose control, but studies in this setting are lacking.<bold>Objective: </bold>To assess the efficacy and safety of the BIHAP in patients after total pancreatectomy.<bold>Design, Setting, and Participants: </bold>This randomized crossover clinical trial compared the fully closed-loop BIHAP with current diabetes care (ie, insulin pump or pen therapy) in 12 adult outpatients after total pancreatectomy. Patients were recruited between August 21 and November 16, 2020. This first-in-patient study began with a feasibility phase in 2 patients. Subsequently, 12 patients were randomly assigned to 7-day treatment with the BIHAP (preceded by a 5-day training period) followed by 7-day treatment with current diabetes care, or the same treatments in reverse order. Statistical analysis was by Wilcoxon signed rank and Mann-Whitney U tests, with significance set at a 2-sided P < .05.<bold>Main Outcomes and Measures: </bold>The primary outcome was the percentage of time spent in euglycemia (70-180 mg/dL [3.9-10 mmol/L]) as assessed by continuous glucose monitoring.<bold>Results: </bold>In total, 12 patients (7 men and 3 women; median [IQR] age, 62.5 [43.1-74.0] years) were randomly assigned, of whom 3 did not complete the BIHAP phase and 1 was replaced. The time spent in euglycemia was significantly higher during treatment with the BIHAP (median, 78.30%; IQR, 71.05%-82.61%) than current diabetes care (median, 57.38%; IQR, 52.38%-81.35%; P = .03). In addition, the time spent in hypoglycemia (<70 mg/dL [3.9 mmol/L]) was lower with the BIHAP (median, 0.00% [IQR, 0.00%-0.07%] vs 1.61% [IQR, 0.80%-3.81%]; P = .004). No serious adverse events occurred.<bold>Conclusions and Relevance: </bold>Patients using the BIHAP after total pancreatectomy experienced an increased percentage of time in euglycemia and a reduced percentage of time in hypoglycemia compared with current diabetes care, without apparent safety risks. Larger randomized trials, including longer periods of treatment and an assessment of quality of life, should confirm these findings.<bold>Trial Registration: </bold>trialregister.nl Identifier: NL8871.
- Subjects
INSULIN therapy; BLOOD sugar monitoring; TYPE 1 diabetes; ARTIFICIAL organs; BLOOD sugar; PANCREATECTOMY; PENICILLIN G; GLUCAGON; HYPOGLYCEMIA; QUALITY of life; CROSSOVER trials
- Publication
JAMA Surgery, 2022, Vol 157, Issue 10, p950
- ISSN
2168-6254
- Publication type
journal article
- DOI
10.1001/jamasurg.2022.3702